Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 11/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 10/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18818621 | 0.90 | RXRA (0.41) | RXRAGRIN1GRIN2BP2RX7CA1 | |
| SCHEMBL20857082 | 0.88 | RXRA (0.48) | RXRAGRIN1GRIN2BP2RX7CA1 | |
| SCHEMBL18818594 | 0.88 | RXRA (0.40) | RXRAGRIN1GRIN2BP2RX7CA1 | |
| SCHEMBL19276551 | 0.88 | RXRA (0.42) | RXRAGRIN1GRIN2BCA1CA2 | |
| SCHEMBL20118087 | 0.86 | RXRA (0.39) | RXRAGRIN1GRIN2BP2RX7CA1 | |
| SCHEMBL22859650 | 0.85 | RXRA (0.37) | RXRAGRIN1GRIN2BP2RX7CA1 | |
| SCHEMBL19734912 | 0.85 | NOTUM (0.44) | RXRAGRIN1GRIN2BCA1CA2 | |
| SCHEMBL24029307 | 0.84 | RXRA (0.42) | RXRAGRIN1GRIN2BP2RX7CA1 | |
| SCHEMBL17482381 | 0.84 | CA2 (0.43) | RXRAGRIN1GRIN2BCA1CA2 | |
| SCHEMBL20047076 | 0.84 | CA1 (0.43) | RXRAGRIN1GRIN2BP2RX7CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287341-A1 | GENETICALLY MODIFIED CELL LINES EXPRESSING AN EXOGENOUS SUBSTANCE AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20220000789-A1 | IMPLANTABLE DEVICES FOR CELL THERAPY AND RELATED METHODS | SIGILON THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-20210145759-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20210002433-A1 | BIOCOMPATIBLE HYDROGEL CAPSULES AND PROCESS FOR PREPARING SAME | SIGILON THERAPEUTICS, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SLC10A1, SLCO1B3, SLC5A1 | RXRA 1225/4885GRIN1 1183/4885GRIN2B 924/4885 |
| US-20210002433-A1 | BIOCOMPATIBLE HYDROGEL CAPSULES AND PROCESS FOR PREPARING SAME | ACMSD, ALG1, COL2A1 | RXRA 2890/4885GRIN1 3948/4885GRIN2B 3839/4885 |
| US-20210145759-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | TNNT2, TNNI3, TNNC1 | RXRA 891/4885GRIN1 2238/4885GRIN2B 1320/4885 |
| US-20220000789-A1 | IMPLANTABLE DEVICES FOR CELL THERAPY AND RELATED METHODS | CD47, CALR, NPSR1 | RXRA 1299/4885GRIN1 3603/4885GRIN2B 2621/4885 |
| US-20230287341-A1 | GENETICALLY MODIFIED CELL LINES EXPRESSING AN EXOGENOUS SUBSTANCE AND USES THEREOF | ZFX, XPA, CTCF | RXRA 153/4885GRIN1 1739/4885GRIN2B 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.